Centocor deals boosts Johnson & Johnson's cardiac business
This article was originally published in Clinica
Johnson & Johnson is to buy US biotechnology company Centocor in a stock swap worth $4.9 billion. The deal comes two months after the failure of an earlier merger attempt between the two companies. Shares in Centocor rose around 16% to $57.56 on the news.